title: 5- to 16-year follow-up following splenectomy in chronic immune thrombocytopenic purpura in children.
abstract: The long-term outcome after splenectomy in children with chronic immune thrombocytopenic purpura (ITP) has not been widely analyzed. We reviewed the medical records of 288 children and adolescents with chronic ITP between 1980 and 1996: 112 were splenectomized; 59 were steroid resistant and 42 were steroid dependent, and 11 were managed with repeated courses of intravenous immunoglobulin (IVIG). All had platelet counts (PCs) <30 x 10(9)/l with frequent bleeding episodes or persistent thrombocytopenia <10 x 10(9)/l. Ninety-eight patients (88%) were evaluated; 58 (60%) patients had never received immunotherapy for ITP following splenectomy. At 5 years, 44 (45%) remained in complete response (CR) and 34 (35%) in partial response (PR). In multivariate analysis, steroid-resistant patients were more likely to relapse after an initial CR (RR 5.2).
  
  
  CONCLUSIONS
  The long-term CR was 45%; 60% had stable PCs >30 x 10(9)/l not requiring therapy. Most postsplenectomy relapses occurred during the 1st year. Initial response to steroids and IVIG prior to splenectomy was a predictor of long-term response to splenectomy.
authors.affiliation: Hematology-Oncology Clinic, Children's Hospital, Ain Shams University, Cairo, Egypt. elalfym@hotmail.com
authors.forename: Mohsen S
authors.initials: MS
authors.lastname: El-Alfy
authors.forename: Mohamed M
authors.initials: MM
authors.lastname: El-Tawil
authors.forename: Naglaa
authors.initials: N
authors.lastname: Shahein
mesh_terms: D000293:Adolescent; D002648:Child; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016756:Immunoglobulins, Intravenous; D008297:Male; D015999:Multivariate Analysis; D011379:Prognosis; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy / Q000401:mortality* / Q000601:surgery*; D012008:Recurrence; D012189:Retrospective Studies; D013156:Splenectomy; D013256:Steroids / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous; D013256:Steroids